Provectus News

Phase 2 Safety and Efficacy Data To Be Presented on Provectus' PV-10 at 7th International Melanoma Research Congress on November 4, 2010
Monday September 13, 2010
 

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, whose agenda can be found at:

(http://www.melanoma2010.com/pdf/Melanoma_Centres_program.pdf)

Efficacy data on the full study population will be presented, including response rate and time-to-event (progression-free- survival and overall survival). Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, and Principal Investigator for Provectus's Phase 2 PV-10 trial site at St. Luke's, will be delivering the presentation.

Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, "The final follow-up on all 80 subjects enrolled in the Phase 2 study was completed in May 2010. We are extremely excited about the efficacy, progression-free-survival and overall survival data to be presented, which we believe will be comparable to the interim data presented at the ASCO meeting in June. These data confirm our belief that PV-10 compares favorably with available and emerging options for this patient population, making it an attractive candidate for commercial development, and we look forward to Dr. Agarwala’s presentation."

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and liver metastases. The Company has received orphan drug designation from the FDA for its melanoma indication. Its dermatological drugs also target abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed its Phase 2 trials -- PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

Contact:

Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
CFO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
VP - Investor Relations
or
Bill Gordon, 212-564-4700
SVP - Media Relations